

Global NIPT Market: Focus on Test Type, Platform, Method, Application, End-User, 5 Regional Data, 25 Countries' Data, Competitive Landscape, Regulatory and Reimbursement Scenario - Analysis and Forecast, 2020-2030

<https://marketpublishers.com/r/GF6F373EC42DEN.html>

Date: September 2020

Pages: 332

Price: US\$ 5,000.00 (Single User License)

ID: GF6F373EC42DEN

Abstracts

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at order@marketpublishers.com with your request.

Market Report Coverage - Global NIPT

Market Segmentation

By Test – Panorama and Vistara, MaterniT GENOME, MaterniT 21 PLUS, informaSeq, Verifi and Verifi Plus Prenatal Tests; Harmony Test; NIFTY Test and NIFTY Test Pro; QNatal Advanced; PrenaTest, GeneSafe, and PrenatalSAFE; Bambni Test; IONA and Sage; and Others

By Platform– PCR, Next-Generation Sequencing, and Others

By Method – cfDNA and FCMB

By End User – Hospitals, Clinics, Diagnostic Labs, and Others

By Application – Trisomy Detection, Microdeletion Detection, Sex Chromosome Aneuploidy Detection, Others

Regional Segmentation

North America – U.S., Canada

Europe – Germany, U.K., France, Italy, Switzerland, Spain, The Netherlands, Belgium, Russia, Poland, Denmark, Sweden, and Rest-of-Europe

Asia-Pacific – China, Australia, Japan, India, South Korea, Hong Kong, Malaysia, Indonesia, Vietnam, Thailand, Philippines, and Rest-of-Asia-Pacific

Latin America

Rest-of-the-World

Growth Drivers

Increased emphasis on early detection and prevention

Availability of advanced screening technologies

Increasing consumer demand

Shifting of reimbursement policies toward more genetics coverage

High incidence rate of Down syndrome

Rising average maternal age

Increasing prevalence of genetic and congenital disorders

Market Challenges

Stringent regulatory guidelines and ethical hurdles

Limitations of NIPT

Lack of awareness among consumers

Alternative screening and testing methods

Market Opportunities

Capitalizing on the potential presented by the emerging markets of Asia

Availability of direct to consumer tests

Focus toward pre-implantation genetic diagnosis

Key Companies Profiled

Agilent Technologies, Inc., BGI, CENTOGENE N.V., Eurofins Scientific, F. Hoffmann-La Roche Ltd., Illumina, Inc., Laboratory Corporation of America Holdings, Natera, Inc., PerkinElmer Inc., Quest Diagnostics Incorporated, Annoroad Gene Technology, MedGenome Inc., Myriad Genetics, Inc., Next Biosciences, and Yourgene Health PLC

Key Questions Answered in this Report:

What is the importance of NIPT, and what are the different NIPT products/services available in the market? What are the different methods of NIPT, and what are the benefits and risks associated with it?

What are the major technological advancements witnessed by the global NIPT market in the past four years, and what is the future scope of the market? What are the key trends of the global NIPT market as per the year 2020, and how is the market evolving currently?

What were the market size and market volume of the global NIPT market in 2019, and what are the market size and market volume anticipated to be in 2030? What is the expected growth rate of the global NIPT market during the period between 2020 and 2030?

What is the market scenario and growth potential of different regions of the world, including North America, Europe, Asia-Pacific, and Rest-of-the-World?

What are the major drivers, challenges, and opportunities of the global NIPT market?

What are the major key players of the global NIPT market? How much market share does each of these players occupy in the market in 2019? Which companies are anticipated to be highly disruptive in the future, and why?

What is the regulatory scenario of the global NIPT market? What are the initiatives implemented by different governmental bodies and guidelines put forward to regulate the commercialization of NIPT products?

What is the average NIPT cost in different countries? What is the reimbursement scenario of the global NIPT market, and what is the reimbursement rate in different countries of the world, including countries of North America, Latin America, Asia-Pacific, Europe, and Middle East and Africa?

What is the funding scenario of the market with respect to institutional and academic funding? What is the patent landscape of the market, and which companies stand out for registering the maximum number of patents?

What are the key developmental strategies implemented by the key players of the global NIPT market to sustain the competition of the market? What is the percentage share of each of the key players in different key developmental strategies?

What are the different NIPT tests available in the market, and which test type dominates the market in 2019 and 2030 in terms of value and volume?

What is the global market size (by value and volume) of different types of products of the global NIPT market in 2019? What are the key trends of the market with respect to different kits, assays, and which product is expected to dominate the market in 2030?

What are the different technologies/platforms supported by NIPT products? Which technology type dominated the market in 2019 and is expected to dominate in 2030 (by value and volume)?

What are the different applications associated with NIPT? What was the contribution of each of the application areas in the global NIPT market for the

time period between 2019 and 2030 (by value and volume)?

How is the global NIPT market segmented based on different methods (by value and volume)? Which method is currently leading the market, and why? Which method is expected to lead the market during the forecast?

What are the different end-users of the global NIPT market (by value and volume)? Which end-user type is the major contributor to the total revenue in the market?

Which region is expected to contribute the highest sales in the global NIPT market between 2019 and 2030? What are the leading countries of different regions (by revenue and volume) that contribute significantly toward the growth of the NIPT market?

Market Overview

Non-invasive prenatal testing (NIPT) is a sophisticated method used for the screening of chromosomal abnormalities developing in the fetus. Currently, NIPT is considered a valuable test for the pregnant women to provide cost-effective and highly efficient early diagnosis of genetic disorders. Moreover, advancements in genome sequencing technologies reduce turnaround time and the complexity of diagnosis with next generation sequencing (NGS). The NGS technology provides several opportunities to develop the non-invasive diagnostic procedures for an early and accurate detection of various genetic disorders. The life science industry is witnessing significant growth of NIPT tests developed using the NGS technology. Several biotechnology companies are now indulging in the research and development of such NGS-based NIPT products. Furthermore, the advent of genome sequencing technologies in the life science industry has enabled the companies to detect the genetic diseases at an early stage and provide accurate results to remain competitive in the market.

Our healthcare experts have found global NIPT market as one of the most rapidly evolving markets amongst the other prenatal testing industries. The purpose of this study is to gain a holistic view of the NIPT market in terms of various influencing factors, such as recent trends, regulatory requirements, and technological advancements of the market. The scope of this report constitutes a detailed study of the tests associated with the global NIPT market across different regions. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in

forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

This research report aims at answering various aspects of the global NIPT market with the help of the key factors driving the market, restraints, and challenges that can inhibit the overall market growth and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.

Within the research report, the market has been segmented into 'tests,' 'methods,' 'platforms,' 'applications,' 'end-user', and 'regions.'. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The NIPT market is currently at a blooming phase, with the presence of various juggernauts such as F. Hoffmann-La Roche Ltd, Illumina, Inc., Agilent Technologies, Inc., BGI, Laboratory Corporation of America Holdings, and PerkinElmer Inc., as well as other medium and small-medium enterprises, that are offering wide range of NIPT products and services in the market. Several companies are attempting to enter the market and sustain themselves in the competition by adopting different strategies varying from partnerships and collaborations to business expansions and product launches.

Contents

1 PRODUCT DEFINITION

1.1 Inclusion and Exclusion

2 SCOPE OF THE WORK

2.1 Overview: Report Scope

2.2 Segmentation of the Global NIPT Market

2.3 Assumptions and Limitations

2.4 Key Questions Answered in the Report

2.5 Base Year and Forecast Period

3 RESEARCH METHODOLOGY

3.1 Overview: Report Methodology

3.2 Primary Data Sources

3.3 Secondary Data Sources

3.4 Market Estimation Model

3.5 Criteria for Company Profiling

4 MARKET OVERVIEW

4.1 Introduction

4.2 Factors Influencing the Adoption of NIPT

4.3 NIPT Approach

4.4 Different Methods of NIPT

4.5 Benefits and Risks Associated with NIPT

4.6 Chromosomal Aneuploidy

4.7 Features and Incidence Rate of Major Chromosomal Aneuploidies

4.8 Technological Advancements

4.9 World Economic Outlook of Prenatal Testing Market, 2019

4.10 Global Footprint

5 MARKET DYNAMICS

5.1 Overview

5.2 Impact Analysis

5.3 Market Drivers

- 5.3.1 Increased Emphasis on Early Detection and Prevention
- 5.3.2 Availability of Advanced Screening Technologies
- 5.3.3 Increasing Consumer Demand
- 5.3.4 Shifting of Reimbursement Policies Toward More Genetics Coverage
- 5.3.5 High Incidence Rate of Down's Syndrome
- 5.3.6 Rising Average Maternal Age
- 5.3.7 Increasing Prevalence of Genetic and Congenital Disorders

5.4 Market Restraints

- 5.4.1 Stringent Regulatory Guidelines and Ethical Hurdles
- 5.4.2 Limitations of NIPT
- 5.4.3 Lack of Awareness Among Consumers
- 5.4.4 Alternative Screening and Testing Methods

5.5 Market Opportunities

- 5.5.1 Capitalizing on the Potential Presented by the Emerging Markets of Asia
- 5.5.2 Availability of Direct to Consumer Tests
- 5.5.3 Focus on Pre-Implantation Genetic Diagnosis

6 INDUSTRY INSIGHTS

6.1 Regulatory Framework

- 6.1.1 Regulatory Scenario in the U.S.
- 6.1.2 Regulatory Scenario in Canada
- 6.1.3 Regulatory Scenario in the U.K.
- 6.1.4 Regulatory Scenario in Germany
- 6.1.5 Regulatory Scenario in France
- 6.1.6 Regulatory Scenario in Spain
- 6.1.7 Regulatory Scenario in Italy
- 6.1.8 Regulatory Scenario in the Netherlands
- 6.1.9 Regulatory Scenario in China
- 6.1.10 Regulatory Scenario in India
- 6.1.11 Regulatory Scenario in Australia
- 6.1.12 Regulatory Scenario in Japan

6.2 Clinical Laboratory Improvement Amendments (CLIA) Program

- 6.2.1 Regulatory Authorities Involved in CLIA Program

6.3 Cost and Access

6.4 Reimbursement Scenario

6.5 Funding Scenario

6.6 Supply Chain

6.7 Impact of COVID-19 Outbreak on the Global NIPT Market

7 COMPETITIVE LANDSCAPE

7.1 Overview

7.2 Key Developments and Strategies

7.2.1 New Offerings

7.2.2 Partnerships and Alliances

7.2.3 Product Approval

7.2.4 Business Expansion

7.2.5 M&A Activities

7.2.6 Others

7.3 Market Share Analysis

7.4 Growth Share Analysis (Opportunity Mapping)

7.4.1 By Platform

8 GLOBAL NIPT MARKET (BY TEST), 2019-2030

8.1 Overview

8.2 Panorama and Vistara

8.3 MaterniT GENOME, MaterniT 21 PLUS, and informaSeq

8.4 Verifi and Verifi Plus Prenatal Tests

8.5 Harmony Test

8.6 NIFTY Test and NIFTY-Test Pro

8.7 QNatal Advanced

8.8 PrenaTest, GeneSafe, and PrenatalSAFE

8.9 Bambni Test

8.10 IONA and Sage

8.11 Others

9 GLOBAL NIPT MARKET (BY METHOD), 2019-2030

9.1 Overview

9.2 cfDNA

9.3 FCMB

10 GLOBAL NIPT MARKET (BY PLATFORM), 2019-2030

10.1 Overview

10.2 Next-Generation Sequencing

10.3 PCR

10.4 Others

11 GLOBAL NIPT MARKET (BY APPLICATION), 2019-2030

11.1 Overview

11.2 Trisomy Detection

11.3 Microdeletion Detection

11.4 Sex Chromosome Aneuploidy Detection

11.5 Others

12 GLOBAL NIPT MARKET (BY END USER), 2019-2030

12.1 Overview

12.2 Hospitals

12.3 Clinics

12.4 Diagnostic Labs

12.5 Others

13 GLOBAL NIPT MARKET (BY REGION), 2019-2030

13.1 Overview

13.2 North America

13.2.1 Overview

13.2.2 U.S.

13.2.3 Canada

13.3 Europe

13.3.1 Overview

13.3.2 Germany

13.3.3 France

13.3.4 Italy

13.3.5 U.K.

13.3.6 Spain

13.3.7 Russia

13.3.8 Poland

13.3.9 Netherlands

13.3.10 Belgium

13.3.11 Switzerland

- 13.3.12 Denmark
- 13.3.13 Sweden
- 13.3.14 Rest-of-Europe
- 13.4 Asia-Pacific
 - 13.4.1 Overview
 - 13.4.2 China
 - 13.4.3 Japan
 - 13.4.4 India
 - 13.4.5 Australia
 - 13.4.6 South Korea
 - 13.4.7 Hong Kong
 - 13.4.8 Malaysia
 - 13.4.9 Indonesia
 - 13.4.10 Vietnam
 - 13.4.11 Thailand
 - 13.4.12 Philippines
 - 13.4.13 Rest-of-APAC
- 13.5 Latin America
- 13.6 Rest-of-the-World

14 COMPANY PROFILES

- 14.1 Overview
- 14.2 Agilent Technologies, Inc.
 - 14.2.1 Company Overview
 - 14.2.2 Role of Agilent Technologies, Inc. in the Global NIPT Market
 - 14.2.3 Financials
 - 14.2.4 Key Insights About Financial Health of the Company
 - 14.2.5 SWOT Analysis
- 14.3 F. Hoffmann-La Roche Ltd
 - 14.3.1 Company Overview
 - 14.3.2 Role of F. Hoffmann-La Roche Ltd in the Global NIPT Market
 - 14.3.3 Financials
 - 14.3.4 Key Insights About Financial Health of the Company
 - 14.3.5 SWOT Analysis
- 14.4 PerkinElmer, Inc.
 - 14.4.1 Company Overview
 - 14.4.2 Role of PerkinElmer, Inc. in the Global NIPT Market
 - 14.4.3 Financials

- 14.4.4 Key Insights About Financial Health of the Company
- 14.4.5 SWOT Analysis
- 14.5 Quest Diagnostics Incorporated
 - 14.5.1 Company Overview
 - 14.5.2 Role of Quest Diagnostics Incorporated in the Global NIPT Market
 - 14.5.3 Financials
 - 14.5.4 SWOT Analysis
- 14.6 Illumina, Inc.
 - 14.6.1 Company Overview
 - 14.6.2 Role of Illumina, Inc. in the Global NIPT Market
 - 14.6.3 Financials
 - 14.6.4 Key Insights About Financial Health of the Company
 - 14.6.5 SWOT Analysis
- 14.7 Myriad Genetics, Inc.
 - 14.7.1 Company Overview
 - 14.7.2 Role of Myriad Genetics, Inc. in the NIPT Market
 - 14.7.3 Financials
 - 14.7.4 Key Insights About Financial Health of the Company
 - 14.7.5 SWOT Analysis
- 14.8 BGI
 - 14.8.1 Company Overview
 - 14.8.2 Role of BGI in the NIPT Market
 - 14.8.3 SWOT Analysis
- 14.9 CENTOGENE N.V.
 - 14.9.1 Company Overview
 - 14.9.2 Role of CENTOGENE N.V. in the NIPT Market
 - 14.9.3 Financials
 - 14.9.4 Key Insights About Financial Health of the Company
 - 14.9.5 SWOT Analysis
- 14.10 Laboratory Corporation of America Holdings
 - 14.10.1 Company Overview
 - 14.10.2 Role of Laboratory Corporation of America Holdings in the NIPT Market
 - 14.10.3 Financials
 - 14.10.4 SWOT Analysis
- 14.11 MedGenome Inc.
 - 14.11.1 Company Overview
 - 14.11.2 Role of MedGenome Inc. in the Global NIPT Market
 - 14.11.3 SWOT Analysis
- 14.12 Annoroad Gene Technology

- 14.12.1 Company Overview
- 14.12.2 Role of Annoroad Gene Technology in the NIPT Market
- 14.12.3 SWOT Analysis
- 14.13 Natera, Inc.
 - 14.13.1 Company Overview
 - 14.13.2 Role of Natera, Inc. in the Global NIPT Market
 - 14.13.3 Financials
 - 14.13.4 Key Insights About Financial Health of the Company
 - 14.13.5 SWOT Analysis
- 14.14 Yourgene Health PLC
 - 14.14.1 Company Overview
 - 14.14.2 Role of Yourgene Health PLC in the NIPT Market
 - 14.14.3 Financials
 - 14.14.4 SWOT Analysis
- 14.15 Next Biosciences
 - 14.15.1 Company Overview
 - 14.15.2 Role of Next Biosciences in the NIPT Market
 - 14.15.3 SWOT Analysis
- 14.16 Eurofins Scientific
 - 14.16.1 Company Overview
 - 14.16.2 Role of Eurofins Scientific in the NIPT Market
 - 14.16.3 Financials
 - 14.16.4 SWOT Analysis

List Of Tables

LIST OF TABLES

Table 1: Leading Segments of the Global NIPT Market (by Revenue), 2019 and 2030

Table 4.1: Major Chromosomal Aneuploidies

Table 4.2: Technological Approach for NIPT

Table 5.1: Impact Analysis of Market Drivers

Table 5.2: Impact Analysis of Market Restraints

Table 5.3: Risk of Chromosomal Abnormality w.r.t Maternal Age

Table 6.1: 12. List of Regulatory Authorities Involved in CLIA Program

Table 6.2: Major Funding Activities (January 2017-June 2020)

Table 9.1: Key Companies Offering cfDNA-Based NIPT Solution

Table 9.2: Key Companies Offering FCMB-Based NIPT Solution

Table 10.1: Key Companies Offering NGS-Based NIPT Solution

Table 10.2: Key Companies Offering PCR-Based NIPT Solution

Table 10.3: Key Companies Offering Other Platform-Based NIPT Solution

Table 11.1: Key Companies Offering NIPT Solution for Trisomy Detection

Table 11.2: Key Companies Offering NIPT Solution for Microdeletion Detection

Table 11.3: Key Companies Offering NIPT Solution for SCA Detection

List Of Figures

LIST OF FIGURES

- Figure 1: Global NIPT Testing Market (by Region), by Revenue, 2019 and 2030
- Figure 2: Global NIPT Testing Market (by Region), by Volume, 2019 and 2030
- Figure 3: Impact of Market Drivers and Market Restraints
- Figure 4: Market Statistics
- Figure 5: Global NIPT Market Share (by Test), 2019-2030
- Figure 6: Global NIPT Market Share (by Method), 2019-2030
- Figure 7: Global NIPT Market Share (by Platform), 2019-2030
- Figure 8: Global NIPT Market Share (by Application), 2019-2030
- Figure 9: Global NIPT Market Share (by End User), 2019-2030
- Figure 2.1: Global NIPT Market Segmentation
- Figure 3.1: Global NIPT Market Methodology
- Figure 3.2: Primary Research Methodology
- Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
- Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
- Figure 4.1: Prenatal Testing Timeline During Pregnancy
- Figure 4.2: Different Indications for NIPT
- Figure 4.3: NIPT Approach
- Figure 4.4: Benefits and Risks of NIPT
- Figure 4.5: Features of The Major Chromosome Aneuploidies
- Figure 4.6: Incidence Rate of The Major Chromosome Aneuploidies
- Figure 4.7: Ecosystem Players of Global Prenatal Testing Market
- Figure 4.8: Global NIPT Market, by Value
- Figure 4.9: Global NIPT Market, by Volume
- Figure 5.1: Births with Down's Syndrome per 100 000 live births in European Region (2011-2018)
- Figure 5.2: Examples of Investment and Funding by Key Companies
- Figure 6.1: Classification of Tests in CLIA Program
- Figure 6.2: Cost Range of NIPT in Major Countries
- Figure 6.3: Reimbursement Scenario in Major Countries of the Global NIPT Market
- Figure 6.4: Supply Chain of Global NIPT Market
- Figure 6.5: The Growth Trend of the Global NIPT Market as was Expected in the Absence of COVID-19 and the Expected Growth Rate due to COVID-19 Outbreak, 2019-2030
- Figure 7.1: Competitive Landscape (January 2017-April 2020)
- Figure 7.2: Share of Key Developments and Strategies, January 2017-June 2020

- Figure 7.3: New Offerings (by Company), January 2017 and June 2020
- Figure 7.4: Partnerships and Alliances (by Company), January 2017 and June 2020
- Figure 7.5: Product Approvals (by Company), January 2017 and June 2020
- Figure 7.6: Business Expansion (by Company), January 2017 and June 2020
- Figure 7.7: M & A Activities (by Company), January 2017 and June 2020
- Figure 7.8: Market Share Analysis of Global NIPT Market, 2019
- Figure 7.9: Growth Share Matrix for NIPT Market (by Platform), 2018-2019
- Figure 8.1: Global NIPT Segmentation (by Test)
- Figure 8.2: Global NIPT Market (by Test) by Revenue, 2019-2030
- Figure 8.3: Global NIPT Market for Panorama and Vistara (by Revenue), 2019-2030
- Figure 8.4: Global NIPT Market for Panorama and Vistara (by Revenue), 2019-2030
- Figure 8.5: Global NIPT Market for Verifi and Verifi Plus Prenatal Tests (by Revenue), 2019-2030
- Figure 8.6: Global NIPT Market for Harmony Test, by Revenue, 2019-2030
- Figure 8.7: Global NIPT Market for NIFTY Test and NIFTY Test Pro (by Revenue), 2019-2030
- Figure 8.8: Global NIPT Market for QNatal Advanced (by Revenue), 2019-2030
- Figure 8.9: Global NIPT Market for PrenaTest, GeneSafe, and PrenatalSAFE (by Revenue), 2019-2030
- Figure 8.10: Global NIPT Market for Bambni Test (by Revenue), 2019-2030
- Figure 8.11: Global NIPT Market for IONA and Sage (by Revenue), 2019-2030
- Figure 8.12: Global NIPT Market for Other Tests (by Revenue), 2019-2030
- Figure 9.1: Global NIPT Segmentation (by Method)
- Figure 9.2: Global NIPT Market (by Method), by Revenue, 2019-2030
- Figure 9.3: Global NIPT Market (by Method), by Volume, 2019-2030
- Figure 9.4: Global NIPT Market for cfDNA (by Revenue), 2019-2030
- Figure 9.5: Global NIPT Market for cfDNA (by Volume), 2019-2030
- Figure 9.6: Global NIPT Market for FCMB (by Revenue), 2019-2030
- Figure 9.7: Global NIPT Market for FCMB (by Volume), 2019-2030
- Figure 10.1: Global NIPT Segmentation (by Platform)
- Figure 10.2: Global NIPT Market (by Platform), by Revenue, 2019-2030
- Figure 10.3: Global NIPT Market (by Platform), by Volume, 2019-2030
- Figure 10.4: Global NIPT Market for NGS (by Revenue), 2019-2030
- Figure 10.5: Global NIPT Market for NGS (by Volume), 2019-2030
- Figure 10.6: Global NIPT Market for PCR (by Revenue), 2019-2030
- Figure 10.7: Global NIPT Market for PCR (by Volume), 2019-2030
- Figure 10.8: Global NIPT Market for Other Platforms (by Revenue), 2019-2030
- Figure 10.9: Global NIPT Market for Other Platforms (by Volume), 2019-2030
- Figure 11.1: Global NIPT Segmentation (by Application)

- Figure 11.2: Global NIPT Market (by Application), by Revenue, 2019-2030
- Figure 11.3: Global NIPT Market (by Application), by Volume, 2019-2030
- Figure 11.4: Global NIPT Market for Trisomy Detection (by Revenue), 2019-2030
- Figure 11.5: Global NIPT Market for Trisomy Detection (by Volume), 2019-2030
- Figure 11.6: Global NIPT Market for Microdeletion Detection (by Revenue), 2019-2030
- Figure 11.7: Global NIPT Market for Microdeletion Detection (by Volume), 2019-2030
- Figure 11.8: Global NIPT Market for Sex Chromosome Aneuploidy Detection (by Revenue), 2019-2030
- Figure 11.9: Global NIPT Market for Sex Chromosome Aneuploidy Detection (by Volume), 2019-2030
- Figure 11.10: Global NIPT Market for Others (by Revenue), 2019-2030
- Figure 11.11: Global NIPT Market for Others (by Volume), 2019-2030
- Figure 12.1: Global NIPT Segmentation (by End User)
- Figure 12.2: Global NIPT Market (by End User), by Revenue, 2019-2030
- Figure 12.3: Global NIPT Market (by End User), by Volume, 2019-2030
- Figure 12.4: Global NIPT Market for Hospitals (by Revenue), 2019-2030
- Figure 12.5: Global NIPT Market for Hospitals (by Volume), 2019-2030
- Figure 12.6: Global NIPT Market for Clinics (by Revenue), 2019-2030
- Figure 12.7: Global NIPT Market for Clinics (by Volume), 2019-2030
- Figure 12.8: Global NIPT Market for Diagnostic Labs (by Revenue), 2019-2030
- Figure 12.9: Global NIPT Market for Hospitals (by Volume), 2019-2030
- Figure 12.10: Global NIPT Market for Others (by Revenue), 2019-2030
- Figure 12.11: Global NIPT Market for Others (by Volume), 2019-2030
- Figure 13.1: Global NIPT Market (by Region), by Revenue, 2019 and 2030
- Figure 13.2: Global NIPT Market (by Region), 2019-2030
- Figure 13.3: Global NIPT Market (by Region), by Volume, 2019 and 2030
- Figure 13.4: Global NIPT Market (by Region), 2019-2030
- Figure 13.5: North America: NIPT Market (by Revenue), 2019-2030
- Figure 13.6: North America: NIPT Market (by Volume), 2019-2030
- Figure 13.7: North America: Market Dynamics
- Figure 13.8: North America: NIPT Market Share (by Country), by Revenue, 2019 and 2030
- Figure 13.9: North America: NIPT Market Share (by Country), by Volume, 2019 and 2030
- Figure 13.10: U.S. NIPT Market (by Revenue), 2019-2030
- Figure 13.11: U.S. NIPT Market (by Volume), 2019-2030
- Figure 13.12: Canada NIPT Market (by Revenue), 2019-2030
- Figure 13.13: Canada NIPT Market (by Volume), 2019-2030
- Figure 13.14: Europe: NIPT Market (by Revenue) and Volume, 2019-2030

- Figure 13.15: Europe NIPT Market (by Revenue and Volume), 2019-2030
- Figure 13.16: Europe Market Dynamics
- Figure 13.17: Europe: NIPT Market Share (by Country), by Revenue, 2019 and 2030
- Figure 13.18: Europe: NIPT Market Share (by Country), by Volume, 2019 and 2030
- Figure 13.19: Germany NIPT Market (by Revenue), 2019-2030
- Figure 13.20: Germany NIPT Market (by Volume), 2019-2030
- Figure 13.21: France NIPT Market (by Revenue and Volume), 2019-2030
- Figure 13.22: France NIPT Market (by Volume), 2019-2030
- Figure 13.23: Italy NIPT Market (by Revenue), 2019-2030
- Figure 13.24: Italy NIPT Market (by Volume), 2019-2030
- Figure 13.25: U.K. NIPT Market (by Revenue), 2019-2030
- Figure 13.26: U.K. NIPT Market (by Volume), 2019-2030
- Figure 13.27: Spain NIPT Market (by Revenue), 2019-2030
- Figure 13.28: Spain NIPT Market (by Volume), 2019-2030
- Figure 13.29: Russia NIPT Market (by Revenue), 2019-2030
- Figure 13.30: Russia NIPT Market (by Volume), 2019-2030
- Figure 13.31: Poland NIPT Market (by Revenue), 2019-2030
- Figure 13.32: Poland NIPT Market (by Volume), 2019-2030
- Figure 13.33: Netherlands NIPT Market (by Revenue), 2019-2030
- Figure 13.34: Netherlands NIPT Market (by Volume), 2019-2030
- Figure 13.35: Belgium NIPT Market (by Revenue), 2019-2030
- Figure 13.36: Belgium NIPT Market (by Volume), 2019-2030
- Figure 13.37: Switzerland NIPT Market (by Revenue), 2019-2030
- Figure 13.38: Switzerland NIPT Market (by Volume), 2019-2030
- Figure 13.39: Denmark NIPT Market (by Revenue), 2019-2030
- Figure 13.40: Denmark NIPT Market (by Volume), 2019-2030
- Figure 13.41: Sweden NIPT Market (by Revenue), 2019-2030
- Figure 13.42: Sweden NIPT Market (by Volume), 2019-2030
- Figure 13.43: Rest-of-Europe NIPT Market (by Revenue), 2019-2030
- Figure 13.44: Rest-of-Europe NIPT Market (by Volume), 2019-2030
- Figure 13.45: APAC NIPT Market (by Revenue), 2019-2030
- Figure 13.46: APAC: NIPT Market (by Volume), 2019-2030
- Figure 13.47: APAC Market Dynamics
- Figure 13.48: APAC NIPT Market Share (by Country), by Revenue, 2019 and 2030
- Figure 13.49: APAC NIPT Market Share (by Country), by Revenue and Volume, 2019 and 2030
- Figure 13.50: China NIPT Market (by Revenue), 2019-2030
- Figure 13.51: China NIPT Market (by Volume), 2019-2030
- Figure 13.52: Japan NIPT Market (by Revenue), 2019-2030

- Figure 13.53: Japan NIPT Market (by Volume), 2019-2030
- Figure 13.54: India NIPT Market (by Revenue), 2019-2030
- Figure 13.55: India NIPT Market (by Volume), 2019-2030
- Figure 13.56: Australia NIPT Market (by Revenue), 2019-2030
- Figure 13.57: Australia NIPT Market (by Volume), 2019-2030
- Figure 13.58: South Korea NIPT Market (by Revenue), 2019-2030
- Figure 13.59: South Korea NIPT Market (by Volume), 2019-2030
- Figure 13.60: Hong Kong NIPT Market (by Revenue), 2019-2030
- Figure 13.61: Hong Kong NIPT Market (by Volume), 2019-2030
- Figure 13.62: Malaysia NIPT Market (by Revenue), 2019-2030
- Figure 13.63: Malaysia NIPT Market (by Volume), 2019-2030
- Figure 13.64: Indonesia NIPT Market (by Revenue), 2019-2030
- Figure 13.65: Indonesia NIPT Market (by Volume), 2019-2030
- Figure 13.66: Vietnam NIPT Market (by Revenue), 2019-2030
- Figure 13.67: Vietnam NIPT Market (by Volume), 2019-2030
- Figure 13.68: Thailand NIPT Market (by Revenue), 2019-2030
- Figure 13.69: Thailand NIPT Market (by Volume), 2019-2030
- Figure 13.70: Philippines NIPT Market (by Revenue), 2019-2030
- Figure 13.71: Philippines NIPT Market (by Volume), 2019-2030
- Figure 13.72: Rest-of-APAC NIPT Market (by Revenue), 2019-2030
- Figure 13.73: Rest-of-APAC NIPT Market (by Volume), 2019-2030
- Figure 13.74: LATAM NIPT Market (by Revenue), 2019-2030
- Figure 13.75: LATAM NIPT Market (by Volume), 2019-2030
- Figure 13.76: R-o-W NIPT Market (by Revenue), 2019-2030
- Figure 13.77: R-o-W NIPT Market (by Volume), 2019-2030
- Figure 14.1: Shares of Key Company Profiles
- Figure 14.2: Agilent Technologies, Inc.: Product Portfolio for Global NIPT Market
- Figure 14.3: Agilent Technologies, Inc.: Overall Financials, 2017-2019
- Figure 14.4: Agilent Technologies, Inc.: Revenue (by Segment), 2017-2019
- Figure 14.5: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
- Figure 14.6: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
- Figure 14.7: Agilent Technologies, Inc.: SWOT Analysis
- Figure 14.8: F. Hoffmann-La Roche Ltd: Product Portfolio for Global NIPT Market
- Figure 14.9: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
- Figure 14.10: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
- Figure 14.11: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
- Figure 14.12: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
- Figure 14.13: F. Hoffmann-La Roche Ltd: SWOT Analysis
- Figure 14.14: PerkinElmer, Inc.: Product Portfolio for Global NIPT Market

- Figure 14.15: PerkinElmer, Inc.: Overall Financials, 2017-2019
- Figure 14.16: PerkinElmer, Inc.: Revenue (by Segment), 2017-2019
- Figure 14.17: PerkinElmer, Inc.: Revenue (by Region), 2017-2019
- Figure 14.18: PerkinElmer, Inc.: R&D Expenditure, 2017-2019
- Figure 14.19: PerkinElmer, Inc.: SWOT Analysis
- Figure 14.20: Quest Diagnostics Incorporated's Product Portfolio for Global NIPT Market
- Figure 14.21: Quest Diagnostics Incorporated -Overall Financials, 2017-2019
- Figure 14.22: Quest Diagnostics Incorporated, Revenue (by Segment), 2017-2019
- Figure 14.23: Quest Diagnostics Incorporated, SWOT Analysis
- Figure 14.24: Illumina, Inc.: Product Portfolio for Global NIPT Market
- Figure 14.25: Illumina, Inc.: Overall Financials, 2017-2019
- Figure 14.26: Illumina, Inc.: Revenue (by Segment), 2017-2019
- Figure 14.27: Illumina, Inc.: Revenue (by Region), 2017-2019
- Figure 14.28: Illumina, Inc.: R&D Expenditure, 2017-2019
- Figure 14.29: Illumina, Inc.: SWOT Analysis
- Figure 14.30: Myriad Genetics, Inc.: Product Portfolio for Global NIPT Market
- Figure 14.31: Myriad Genetics, Inc.: Overall Financials, 2017-2019
- Figure 14.32: Myriad Genetics, Inc.: Revenue (by Product/Service), 2017-2019
- Figure 14.33: Myriad Genetics, Inc.: R&D Expenditure, 2017-2019
- Figure 14.34: Myriad Genetics, Inc.: SWOT Analysis
- Figure 14.35: BGI: Product Portfolio for Global NIPT Market
- Figure 14.36: BGI: SWOT Analysis
- Figure 14.37: CENTOGENE N.V.: Product Portfolio for Global NIPT Market
- Figure 14.38: CENTOGENE N.V.: Overall Financials, 2017-2019
- Figure 14.39: CENTOGENE N.V.: Revenue (by Segment), 2017-2019
- Figure 14.40: CENTOGENE N.V.: Revenue (by Region), 2017-2019
- Figure 14.41: CENTOGENE N.V.: R&D Expenditure, 2017-2019
- Figure 14.42: CENTOGENE N.V.: SWOT Analysis
- Figure 14.43: Laboratory Corporation of America Holdings: Product Portfolio for Global NIPT Market
- Figure 14.44: Laboratory Corporation of America Holdings: Overall Financials, 2017-2019
- Figure 14.45: Laboratory Corporation of America Holdings: Revenue (by Segment), 2017-2019
- Figure 14.46: Laboratory Corporation of America Holdings: Revenue (by Region), 2019
- Figure 14.47: Laboratory Corporation of America Holdings: SWOT Analysis
- Figure 14.48: MedGenome Inc.: Product Portfolio for Global NIPT Market
- Figure 14.49: MedGenome Inc.: SWOT Analysis

Figure 14.50: Annoroad Gene Technology: Product Portfolio for Global NIPT Market

Figure 14.51: Annoroad Gene Technology: SWOT Analysis

Figure 14.52: Natera, Inc.: Product Portfolio for Global NIPT Market

Figure 14.53: Natera, Inc.: Overall Financials, 2017-2019

Figure 14.54: Natera, Inc.: Revenue (by Region), 2017-2019

Figure 14.55: Natera, Inc.: R&D Expenditure, 2017-2019

Figure 14.56: Natera, Inc.: SWOT Analysis

Figure 14.57: Yourgene Health PLC: Product Portfolio for Global NIPT Market

Figure 14.58: Yourgene Health PLC: Overall Financials, 2017-2019

Figure 14.59: Yourgene Health PLC: Revenue (by Region), 2017-2019

Figure 14.60: Yourgene Health PLC: SWOT Analysis

Figure 14.61: Next Biosciences: Product Portfolio for Global NIPT Market

Figure 14.62: Next Biosciences SWOT Analysis

Figure 14.63: Eurofins Scientific: Product Portfolio for Global NIPT Market

Figure 14.64: Eurofins Scientific Overall Financials, 2017-2019

Figure 14.65: Eurofins Scientific Revenue (by Region), 2017-2019

Figure 14.66: Eurofins Scientific: SWOT Analysis

I would like to order

Product name: Global NIPT Market: Focus on Test Type, Platform, Method, Application, End-User, 5 Regional Data, 25 Countries' Data, Competitive Landscape, Regulatory and Reimbursement Scenario - Analysis and Forecast, 2020-2030

Product link: <https://marketpublishers.com/r/GF6F373EC42DEN.html>

Price: US\$ 5,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GF6F373EC42DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970